Cardiovascular toxicities of therapy for genitourinary malignancies
Research output: Contribution to journal › Review article
- University of Pennsylvania
The cardiovascular consequences of systemic cancer therapies are becoming increasingly important for the growing population of patients living with cancer. In particular, patients with genitourinary malignancies are at significant risk for cardiovascular toxicities, due to both prevalent underlying risk factors and the known adverse effects of commonly used therapies. Moreover, improving survival outcomes and novel combination treatment approaches for genitourinary malignancies may predispose to a growing risk for cardiovascular morbidity. As such, knowledge of these potential cardiovascular risks is essential for the optimal care of these patients. This review highlights the cardiovascular toxicities associated with common therapeutic agents for genitourinary malignancies.
- Cardiovascular toxicity, Genitourinary cancers, Survivorship